Method for the Large-Scale Synthesis of Multifunctional 1,4-Dihydro-pyrrolo[3,2‑<i>b</i>]pyrroles حسب Mariusz Tasior (1457731)

"…A thorough investigation has enabled the optimization of the synthesis of 1,4-dihydro-pyrrolo­[3,2-<i>b</i>]­pyrroles. Although salts of such metals as vanadium, niobium, cerium, and manganese were found to facilitate the formation of 1,4-dihydro-pyrrolo­[3,2-<i>b</i>]­pyrroles from amines, aldehydes, and diacetyl, we confirmed that iron salts are the most efficient catalysts. …"

Benchmarking DFT Accuracy in Predicting O 1s Binding Energies on Metals حسب Elizabeth E. Happel (22391811)

الموضوعات:

Benchmarking DFT Accuracy in Predicting O 1s Binding Energies on Metals حسب Elizabeth E. Happel (22391811)

الموضوعات:

The computed weighted sum of type I (dark gray) and type II (light gray) errors ( حسب Farrokh Habibzadeh (12256529)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Maximum temperature and freeze-thaw thickness of surrounding rock (4 °C). حسب Jianqing Jia (21001506)

الموضوعات:

Numerical simulation model. حسب Jianqing Jia (21001506)

الموضوعات:

Reliability and failure probability. حسب Jianqing Jia (21001506)

الموضوعات:

Thermodynamic parameters. حسب Jianqing Jia (21001506)

الموضوعات:

The number of expected vaccinations decreases with the expected vaccination time, whereas the peak of infections increases. حسب Simon K. Schnyder (16632244)

Costs and Benefits of Popular <i>P</i>‑Value Correction Methods in Three Models of Quantitative Omic Experiments حسب Steven R. Shuken (14500192)

"…We show how increasing sample size, decreasing variability, or increasing effect size can enable the detection of all true changes while still correcting <i>p</i>-values, and we present basic guidelines for omic experimental design. …"

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

Species occurrence along the NO₃¯ gradient (sorted by decreasing 25th percentile values). حسب Willem Kaijser (12872371)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Mean values of “I feel bored” item. حسب Ezel Üsten (16548547)

Characterization of the <i>bdp50</i> gene and primary structure of BdP50. حسب Luis Miguel Gonzalez (19432118)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)